← SynDRA
ALECTINIB
SynDRA canonical compound SYN0026649 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | ALK |
|---|
| Mechanism of action | ALK inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- ALK
- RET
- MET
- ABCG2
- FER
- ROS1
- PHKG2
- KDR
- GAK
- EPHA1
- ACOX1
- CSNK1G2
Mechanisms of action (all sources)
- ALK INHIBITOR
- ALK tyrosine kinase receptor inhibitor
- RET INHIBITOR
- Tyrosine-protein kinase receptor RET inhibitor
- MET INHIBITOR
Drug classes
- Kinase Inhibitors
- Kinase Inhibitor
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- alectinib hydrochloride
- alecensa
- CH5424802
- alectinib HCl
- RO5424802
- RO-5424802
- AF-802
- AF802
- Alecensa
- ALECTINIB (CH5424802)
- Alectinib hydrochloride
- ALECTINIBCH-5424802CH5424802CT-CH542
- CH-5424802
- RG-7853
- RG-7853,CH5424802
- RG7853
- CH 5424802
- AF 802
- UNII-LIJ4CT1Z3Y
- LIJ4CT1Z3Y
- Alectinib (CH5424802)
- 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
- CHEMBL1738797
- 9-Ethyl-6,6-Dimethyl-8-[4-(Morpholin-4-Yl)piperidin-1-Yl]-11-Oxo-6,11-Dihydro-5h-Benzo[b]carbazole-3-Carbonitrile
- 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
- AK170451
- C30H34N4O2
- 9-ethyl-6,6-dimethyl-
- 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
- CH5424802(Alectinib)
- ARQ-761
- 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
- Alectinib [INN]
- 9-ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-5h-benzo(b)carbazole-3-carbonitrile
- Alectinib [USAN:INN]
- 5H-BENZO(B)CARBAZOLE-3-CARBONITRILE, 9-ETHYL-6,11-DIHYDRO-6,6-DIMETHYL-8-(4-(4-MORPHOLINYL)-1-PIPERIDINYL)-11-OXO-
- 5H-Benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-
- Alectinib free base
Reported adverse events
- Bradycardia
- Constipation
- Dysgeusia
- Hepatotoxicity
- Myalgia
- Nausea
- Rash
- Vomiting
- Abdominal pain
- Back pain
- Cough
- Fatigue
Look up ALECTINIB in the interactive SynDRA portal →